Background The optimal antithrombotic therapy for patients with atrial fibrillation undergoing
percutaneous coronary intervention is a topic of debate. We aimed at defining the efficacy …

Aims To analyse the safety and efficacy of direct oral anticoagulants (DOACs) in real-world
studies including atrial fibrillation (AF) patients. Methods and results Systematic review and …

Background Four new oral anticoagulants compare favourably with warfarin for stroke
prevention in patients with atrial fibrillation; however, the balance between efficacy and …

Background: The risk-benefit ratio of left atrial appendage closure (LAAC) versus systemic
therapy (warfarin) for prevention of stroke, systemic embolism, and cardiovascular death in …

Background The introduction of non-vitamin K antagonist oral anticoagulants (NOACs) has
been a major advance for stroke prevention in atrial fibrillation (AF). Patients and clinicians …

Background & Aims Direct oral anticoagulant (DOAC) agents increase the risk of
gastrointestinal (GI) bleeding. We investigated which DOAC had the most favorable GI safety …

Background—Fixed-dose unmonitored treatment with dabigatran etexilate is effective and
has a favorable safety profile in the prevention of stroke in atrial fibrillation patients …

Aims The aim of the present meta-analysis was to evaluate the efficacy and safety of non-
vitamin K oral antagonists (NOACs) vs. vitamin K antagonists (VKAs) in elderly patients with …

Background—Trial data for the benefits and risks of dabigatran versus warfarin in the
treatment of nonvalvular atrial fibrillation are lacking. We sought to review real-world …

Background Stroke is the most serious clinical consequence of atrial fibrillation, which is the
most common cardiac arrhythmia. Non-vitamin K antagonist oral anticoagulants (NOACs) …